Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O14617

UPID:
AP3D1_HUMAN

ALTERNATIVE NAMES:
AP-3 complex subunit delta; Adaptor-related protein complex 3 subunit delta-1; Delta-adaptin

ALTERNATIVE UPACC:
O14617; O00202; O75262; Q59HF5; Q96G11; Q9H3C6

BACKGROUND:
AP-3 complex subunit delta-1, known alternatively as AP-3 complex subunit delta or Delta-adaptin, is a key component of the AP-3 adaptor complex. This protein is essential for the budding of vesicles from the Golgi and their trafficking to lysosomes. It also plays a significant role in the degranulation of CD8+ T-cells and NK cells, and in the delivery of cargos into neurites and nerve terminals in coordination with the BLOC-1 complex.

THERAPEUTIC SIGNIFICANCE:
The association of AP-3 complex subunit delta-1 with Hermansky-Pudlak syndrome 10, which leads to severe clinical manifestations such as pulmonary fibrosis and neurodevelopmental delay, underscores the therapeutic potential of targeting this protein. Exploring the mechanisms by which AP-3 complex subunit delta-1 functions could provide valuable insights into novel treatment avenues for this and possibly other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.